Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

Whether intermittent strategies of delivering drugs can improve cancer patients survival is still unclear. Here, the authors reports the results of a randomized phase II clinical trial aimed to compare the efficacy and safety of two dosing regimens (continuous and intermittent) of vemurafenib and co...

Full description

Saved in:

Bibliographic Details
Main Authors:	Maria Gonzalez-Cao, Clara Mayo de las Casas, Juana Oramas, Miguel A. Berciano-Guerrero, Luis de la Cruz, Pablo Cerezuela, Ana Arance, Eva Muñoz-Couselo, Enrique Espinosa, Teresa Puertolas, Roberto Diaz Beveridge, Sebastian Ochenduszko, Maria-Jose Villanueva, Laura Basterretxea, Lorena Bellido, Delvys Rodriguez, Begoña Campos, Clara Montagut, Ana Drozdowskyj, Miguel A. Molina, Jose Antonio Lopez-Martin, Alfonso Berrocal
Format:	article
Language:	EN
Published:	Nature Portfolio 2021
Subjects:	Science Q
Online Access:	https://doaj.org/article/bcf9c314e06143fd83f1b0b564d0166e
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

Similar Items